- Home
- DNP vs SRRK Comparison
DNP vs SRRK Comparison
Compare DNP & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- SRRK
- Stock Information
- Founded
- DNP 1986
- SRRK 2012
- Country
- DNP United States
- SRRK United States
- Employees
- DNP N/A
- SRRK N/A
- Industry
- DNP Investment Managers
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNP Finance
- SRRK Health Care
- Exchange
- DNP Nasdaq
- SRRK Nasdaq
- Market Cap
- DNP 3.7B
- SRRK 3.2B
- IPO Year
- DNP N/A
- SRRK 2018
- Fundamental
- Price
- DNP $9.88
- SRRK $32.55
- Analyst Decision
- DNP
- SRRK Strong Buy
- Analyst Count
- DNP 0
- SRRK 8
- Target Price
- DNP N/A
- SRRK $44.29
- AVG Volume (30 Days)
- DNP 492.8K
- SRRK 2.0M
- Earning Date
- DNP 01-01-0001
- SRRK 08-06-2025
- Dividend Yield
- DNP 7.90%
- SRRK N/A
- EPS Growth
- DNP N/A
- SRRK N/A
- EPS
- DNP 2.30
- SRRK N/A
- Revenue
- DNP $154,887,179.00
- SRRK N/A
- Revenue This Year
- DNP N/A
- SRRK N/A
- Revenue Next Year
- DNP N/A
- SRRK $3,116.02
- P/E Ratio
- DNP $4.30
- SRRK N/A
- Revenue Growth
- DNP 3.30
- SRRK N/A
- 52 Week Low
- DNP $8.69
- SRRK $6.76
- 52 Week High
- DNP $10.04
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- DNP 54.33
- SRRK 50.62
- Support Level
- DNP $9.83
- SRRK $33.01
- Resistance Level
- DNP $9.97
- SRRK $35.87
- Average True Range (ATR)
- DNP 0.05
- SRRK 1.83
- MACD
- DNP 0.00
- SRRK 0.31
- Stochastic Oscillator
- DNP 52.50
- SRRK 78.39
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.